LB Pharmaceuticals, Inc. (LBRX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$38.73-1.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge LB Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.655
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-5.649
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-5.317

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Sufficient funding to support clinical development	A supporting condition in LB Pharmaceuticals, Inc.'s published investment case. The stated target is Maintain cash runway through at least FY28 without dilutive financing.	Under Pressure	Need for dilutive capital raises before FY28	Dilutive raise executed Jul 2026 vs no-dilution target July 2026 private placement of 3,577,560 shares and pre-funded warrants confirms dilutive capital raise. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advancement of clinical-stage therapies in neuropsychiatric diseases	LB Pharmaceuticals is advancing clinical-stage therapies for schizophrenia and bipolar depression.	Intact	Failure or delay in key clinical trial milestones beyond 2027	Qualitative: LB-102 pipeline expansion announced LB-102 aims for safer psychiatry; no negative clinical trial updates or delays found in recent news. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS trend improves toward break-even	A primary condition in LB Pharmaceuticals, Inc.'s published investment case. The stated target is EPS loss narrows from -$3.51 in FY26 to less negative or break-even by FY28.	Broken	EPS loss worsens or remains flat beyond FY26 levels	Diluted EPS: $-1.71 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$3.51 in FY26 to less negative or break-even by FY28. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-1.71 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3b2a021d-2582-466f-ba57-42b106b577bb. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.32

$-4.22 → $-5.32 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.22	Unavailable	5 / 0
2026-07-25	$-4.22	Unavailable	5 / 0
2026-07-26	$-4.22	Unavailable	5 / 0
2026-07-27	$-4.22	Unavailable	5 / 0
2026-07-28	$-4.25	$0	7 / 8
2026-07-29	$-4.25	$0	7 / 8
2026-07-30	$-4.25	$0	7 / 8
2026-07-31	$-4.25	$0	7 / 8
2026-08-01	$-4.22	Unavailable	6 / 0
2026-08-02	$-4.22	Unavailable	6 / 0
2026-08-03	$-4.25	$0	7 / 8
2026-08-04	$-4.25	$0	7 / 8
2026-08-05	$-4.18	$0	7 / 8
2026-08-06	$-4.25	Unavailable	6 / 0
2026-08-07	$-4.25	Unavailable	6 / 0
2026-08-08	$-4.18	$0	7 / 8
2026-08-09	$-4.25	Unavailable	6 / 0
2026-08-10	$-4.25	Unavailable	6 / 0
2026-08-12	$-4.18	$0	7 / 8
2026-08-13	$-4.25	Unavailable	6 / 0
2026-08-14	$-4.25	Unavailable	6 / 0
2026-08-15	$-4.25	Unavailable	6 / 0
2026-08-16	$-4.25	Unavailable	6 / 0
2026-08-17	$-4.25	Unavailable	6 / 0
2026-08-18	$-4.25	Unavailable	6 / 0
2026-08-19	$-4.25	Unavailable	6 / 0
2026-08-20	$-4.96	Unavailable	6 / 0
2026-08-21	$-4.96	Unavailable	6 / 0
2026-08-22	$-4.96	Unavailable	6 / 0
2026-08-23	$-4.96	Unavailable	6 / 0
2026-08-24	$-4.96	Unavailable	6 / 0
2026-08-25	$-5.04	Unavailable	6 / 0
2026-08-26	$-5.04	Unavailable	6 / 0
2026-08-27	$-5.04	Unavailable	6 / 0
2026-08-28	$-5.04	Unavailable	6 / 0
2026-08-29	$-5.04	Unavailable	6 / 0
2026-08-30	$-5.04	Unavailable	6 / 0
2026-08-31	$-5.04	Unavailable	6 / 0
2026-09-01	$-5.04	Unavailable	6 / 0
2026-09-02	$-5.04	Unavailable	6 / 0
2026-09-03	$-5.04	Unavailable	6 / 0
2026-09-04	$-5.04	Unavailable	6 / 0
2026-09-05	$-5.04	Unavailable	6 / 0
2026-09-06	$-5.04	Unavailable	6 / 0
2026-09-07	$-5.04	Unavailable	6 / 0
2026-09-08	$-5.04	Unavailable	6 / 0
2026-09-09	$-5.04	Unavailable	6 / 0
2026-09-10	$-5.04	Unavailable	6 / 0
2026-09-11	$-5.04	Unavailable	6 / 0
2026-09-12	$-5.04	Unavailable	6 / 0
2026-09-13	$-5.04	Unavailable	6 / 0
2026-09-14	$-5.04	Unavailable	6 / 0
2026-09-15	$-5.04	Unavailable	6 / 0
2026-09-16	$-5.04	Unavailable	6 / 0
2026-09-17	$-5.04	Unavailable	6 / 0
2026-09-18	$-5.04	Unavailable	6 / 0
2026-09-19	$-5.04	Unavailable	6 / 0
2026-09-20	$-5.04	Unavailable	6 / 0
2026-09-21	$-5.04	Unavailable	6 / 0
2026-09-22	$-5.04	Unavailable	6 / 0
2026-09-23	$-5.04	Unavailable	6 / 0
2026-09-24	$-5.04	Unavailable	6 / 0
2026-09-25	$-5.04	Unavailable	6 / 0
2026-09-26	$-5.04	Unavailable	6 / 0
2026-09-27	$-5.04	Unavailable	6 / 0
2026-09-28	$-5.04	Unavailable	6 / 0
2026-09-29	$-5.04	Unavailable	6 / 0
2026-09-30	$-5.04	Unavailable	6 / 0
2026-10-01	$-5.04	Unavailable	6 / 0
2026-10-02	$-5.04	Unavailable	6 / 0
2026-10-03	$-5.00	Unavailable	6 / 0
2026-10-04	$-5.00	Unavailable	6 / 0
2026-10-05	$-5.00	Unavailable	6 / 0
2026-10-06	$-5.14	Unavailable	6 / 0
2026-10-07	$-5.36	Unavailable	7 / 0
2026-10-08	$-5.36	Unavailable	7 / 0
2026-10-09	$-5.36	Unavailable	7 / 0
2026-10-10	$-5.36	Unavailable	7 / 0
2026-10-11	$-5.32	Unavailable	8 / 0
2026-10-12	$-5.32	Unavailable	8 / 0
2026-10-13	$-5.32	Unavailable	8 / 0
2026-10-14	$-5.32	Unavailable	8 / 0
2026-10-15	$-5.32	Unavailable	8 / 0
2026-10-16	$-5.32	Unavailable	8 / 0
2026-10-17	$-5.32	Unavailable	8 / 0
2026-10-18	$-5.32	Unavailable	8 / 0
2026-10-19	$-5.32	Unavailable	8 / 0
2026-10-20	$-5.32	Unavailable	8 / 0
2026-10-21	$-5.32	Unavailable	8 / 0
2026-10-22	$-5.32	Unavailable	8 / 0
2026-10-23	$-5.32	Unavailable	8 / 0
2026-10-24	$-5.32	Unavailable	8 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	0
2026-06-01	6	0
2026-07-01	8	0
2026-08-01	8	0
2026-09-01	8	0
2026-10-01	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Canaccord GenuityOct 9

$65.00New observation · no comparable prior

Roth CapitalOct 5 · prior May 17

$37.00 → $35.00-5.4%

GuggenheimOct 5

$80.00New observation · no comparable prior

NeedhamOct 2

$68.00New observation · no comparable prior

$0$44.00$88.00

0 raises · 1 cuts · 0 unchanged · 3 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Sufficient funding to support clinical developmentPublished status: Under Pressure
EPS trend improves toward break-evenPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-31.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

LB Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-stage, loss-making biotech whose multi-year view depends on LB-102 development and pipeline expansion. The thesis is marked intact, but confidence in the evidence is low and near-term risk is elevated.

What's priced into LB Pharmaceuticals, Inc.

The snapshot provides no valuation level or clear evidence about what expectations are already reflected in the market, so whether LBRX looks cheap, fair, or expensive versus peers is unclear. Price reaction to the recent thesis update was muted, and no priced-in fragility gates fired.

What the fundamentals likely do

Management has kept LB-102 milestones on its stated timeline, including Phase 3 NOVA-2 topline data expected in H1 2027, while funding expansion and a runway expected to extend beyond Q2 2029. Near term, the latest earnings miss and a record of recent misses point to elevated risk of another miss; the snapshot gives no detailed financial results to clarify the trend.

What LB Pharmaceuticals, Inc. hinges on

The multi-year thesis hinges on clinical and regulatory progress for LB-102 and on whether new trials expand its potential across neuropsychiatric conditions. Near-term concerns include a possible guidance cut and weaker employment data, while strength among healthcare bellwethers could support sector momentum.